Details of the Drug Reposition

General Information of This Drug (ID: DMTA5OE)

• Drug Name: Azacitidine (DMTA5OE)
• Synonyms: Azacitidina; Azacitidinum; Azacytidine; Ladakamycin; Mylosar; Vidaza; Mylo sar; Pharmion Brand of Azacitidine;A 2385; Antibiotic U 18496; U 18496; Wr 183027; Azacitidina [INN-Spanish]; Azacitidine [USAN:INN]; Azacitidinum [INN-Latin]; NS-17; Pyrimidine antimetabolite: inhibits nucleic acid replication; U-18496; Vidaz (TN); Vidaza (TN); WR-183027; Azacitidine (JAN/USAN/INN); S-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-(8CI); 2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one; 4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one; 4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; 4-amino-1-beta-L-ribofuranosyl-1,3,5-triazin-2(1H)-one; 5 AZC; 5 Azacytidine; 5-AC; 5-AZAC; 5-AZCR; 5-aza-CR; 5-azacitidine; 5-azacytidine; 5-azacytidine, Mylosar, Ladakamycin, Vidaza, Azacitidine; 5AzaC
• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

5 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Leukemia	DISNAKFL	N.A.	Approved	[1]
Chronic myelomonocytic leukemia	DISIL8UR	N.A.	Approved	[1]
Myeloproliferative neoplasm	DIS5KAPA	2A20	Approved	[1]
Acute myelogenous leukaemia	DISCSPTN	2A41	Approved	[1]
Plasma cell myeloma	DIS0DFZ0	2A83.1	Approved	[1]

1 Discontinued in Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Myelodysplastic syndrome	DISYHNUI	2A37	Discontinued in Phase 2	[2]

References

• [1] Azacitidine FDA Label
• [2] Ph II Cabazitaxel DD Liposarcoma